BIOMOLECULAR RESEARCH GENOMICS SRL

Their core work

BMR Genomics is an Italian SME based in Padova that provides genomic sequencing and bioinformatics analysis services, sitting at the intersection of laboratory genomics and computational biology. Their research participation shows capabilities in metagenomics and genome-scale data analysis, including the discovery of novel biocatalysts from environmental samples. Alongside pure research work, they have independently coordinated a project (PLATGENE) to build a digital platform that restructures how geneticists interact with patients carrying Mendelian genetic disorders — pointing to an applied health-tech dimension. In practice, they function as a specialist genomics service provider that can also drive product-oriented innovation, not merely support it.

What they specialise in

How they've shifted over time

BMR Genomics entered H2020 as a specialist research partner in a large MSCA-RISE mobility network (MeTABLE), contributing bioinformatics and genomics capacity to an international academic consortium focused on environmental metagenomics. By 2017, they had shifted to coordinating their own SME-1 feasibility project (PLATGENE), moving from upstream research toward a patient-oriented digital health product. This trajectory — from scientific support role to product coordinator — suggests deliberate commercialisation ambition, even if the H2020 footprint itself remains small.

BMR Genomics is moving from providing sequencing and bioinformatics services within research consortia toward developing proprietary digital tools that connect genomic expertise directly to clinical and patient markets — a shift from B2B research services toward health-tech product ownership.

How they like to work

BMR Genomics has operated in both the participant and coordinator roles across their two projects, showing they can adapt to either position depending on the initiative. Their consortia are small — six partners across five countries in total — which is consistent with the tight, focused teams typical of MSCA-RISE exchanges and SME Instrument phase 1 grants. There is no evidence of repeated partnerships with the same organisations, suggesting they build relationships project by project rather than working within a fixed circle of allies.

BMR Genomics has worked with six distinct partners spread across five countries, a notably international reach for a two-project SME. Their Padova base places them within reach of one of Italy's strongest biomedical and life-science academic clusters, which likely amplifies their informal network beyond what the H2020 record alone shows.

What sets them apart

BMR Genomics occupies an unusual position as a small Italian genomics company that combines laboratory sequencing capacity, computational bioinformatics, and demonstrated ability to build patient-facing digital products — three capabilities that rarely coexist in a single SME. Their PLATGENE coordination shows they can move from service-provider to project-owner when a market opportunity calls for it. For consortium builders in health, biotech, or industrial biotechnology, they offer a specialist genomics node that is already proven in international collaborative settings and capable of contributing across the full data pipeline from wet lab to software.

Highlights from their portfolio

• PLATGENE
  BMR Genomics led this project as coordinator — rare for a two-project SME — targeting a commercially relevant gap between genetic expertise and rare-disease patient access, funded under the competitive SME Instrument phase 1 scheme.
• MeTABLE
  Participation in an MSCA-RISE network spanning multiple countries demonstrates early international research credibility and positions BMR Genomics in the growing field of metagenomics-driven biocatalyst discovery.